Bimagrumab Biosimilar – Anti-ACVR2A, ACVR2B mAb – Research Grade

Description of Bimagrumab Biosimilar - Anti-ACVR2A, ACVR2B mAb - Research Grade

Bimagrumab has been investigated for the treatment of Sarcopenia, Skeletal Muscle, Mechanical Ventilation, Sporadic Inclusion Body Myositis, and Sporadic Inclusion Body Myositis (sIBM).

Bimagrumab Biosimilar – Anti-ACVR2A, ACVR2B mAb – Research Grade binds to ACVR2B in indirect ELISA Assay

Immobilized ACVR2B at 2µg/mL (100µL/well) can bind to Bimagrumab Biosimilar – Anti-ACVR2A, ACVR2B mAb – Research Grade (cat. No.PX-TA1315) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Bimagrumab Biosimilar – Anti-ACVR2A, ACVR2B mAb – Research Grade binds to ACVR2A in indirect ELISA Assay

Immobilized ACVR2A at 2µg/mL (100µL/well) can bind to Bimagrumab Biosimilar – Anti-ACVR2A, ACVR2B mAb – Research Grade (cat. No.PX-TA1315) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450